NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription and Dermatologic & Ophthalmic Drugs advisory committees will discuss clinical trial design and future development programs for drugs treating interdigital Tinea pedis during their May 6-7 meeting in Rockville, MD